SCHEMBL1813150

SCHEMBL1813150

CCOC(=O)CO[C@H]1CCOC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.39
ATF4 P18848 1/20 0.38
TSHR P16473 2/20 0.37
POLB P06746 2/20 0.37
LMNA P02545 1/20 0.37
ALDH1A1 P00352 2/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
PDE4D Q08499 4/20 0.35
PDE4A P27815 3/20 0.35
PDE4B Q07343 3/20 0.35
PDE4C Q08493 3/20 0.35
ITGB3 P05106 3/20 0.35
ITGA2B P08514 3/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TRPA1 O75762 1/20 0.34
PRMT5 O14744 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29214555 1.00 KMT2A (0.39) KMT2AATF4TSHRPOLBLMNA
SCHEMBL1813151 1.00 KMT2A (0.39) KMT2AATF4TSHRPOLBLMNA
SCHEMBL3254867 0.90 TSHR (0.42) KMT2ATSHRPOLBLMNAALDH1A1
SCHEMBL23215046 0.86 MGAM (0.41) KMT2ATSHRPOLBLMNAALDH1A1
SCHEMBL24671886 0.79 ATF4 (0.38) ATF4GAAPDE4DPDE4APDE4B
SCHEMBL29059882 0.79 ATF4 (0.38) ATF4GAAPDE4DPDE4APDE4B
SCHEMBL7892532 0.78 MGAM (0.42) KMT2ATSHRPOLBLMNAALDH1A1
SCHEMBL3248382 0.77 KMT2A (0.51) KMT2ATSHRPOLBALDH1A1MGAM
SCHEMBL3248583 0.77 KMT2A (0.47) KMT2ATSHRPOLBALDH1A1MGAM
SCHEMBL1809033 0.77 ATF4 (0.42) ATF4PDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116669738-A Pyrimidopyridone derivative as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-29 CN disclosed
CN-116568689-A Polycyclic pyrimidine derivative as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-08 CN disclosed
US-20230219951-A1 PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2023-07-13 US disclosed
EP-4166555-A1 PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2023-04-19 EP disclosed
CN-113149961-B Azabicyclo-substituted triazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-11-22 CN disclosed
WO-2022170802-A1 PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2022-08-18 WO disclosed
WO-2021249519-A1 PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF 江苏恒瑞医药股份有限公司 2021-12-16 WO disclosed
CN-113149961-A Azabicyclo-substituted triazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2021-07-23 CN disclosed
CN-109071492-B Azabicyclo-substituted triazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2021-02-26 CN disclosed
US-20210040073-A1 AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2021-02-11 US disclosed
WO-2011061590-A1 NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2011-05-26 WO disclosed
WO-2011061590-A1 NOVEL CARBOXAMIDE DERIVATIVES AS HIV INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040073-A1 AZABICYCLO-SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION OF SAME IN MEDICINE OXTR, CRH, MC2R KMT2A 3400/4885ATF4 1145/4885TSHR 40/4885
US-20230219951-A1 PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF WEE1, SOS1, HINT1 KMT2A 4671/4885ATF4 2221/4885TSHR 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.